Regulus Therapeutics (RGLS) Misses Q3 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08).

As of September 30, 2021, Regulus had $35.8 million in cash and cash equivalents.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal